Publications

Manuscripts

View manuscript (web link)

Burns CJ, et al. The microtubule depolymerising agent CYT997 causes extensive ablation of tumor vasculature in vivo. J Pharmacol Exp Ther 2011 Sep 14 (JPET/2011/186965)

View manuscript (web link)

Lickliter JD, et al. Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. Br J Cancer 2010 Aug 24; 103: 597-606

View manuscript (web link)

Monaghan K, et al. CYT997 causes apoptosis in human multiple myeloma. Invest New Drugs 2009 Nov 12

View manuscript (web link)

Burns CJ, et al. CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo. Mol Cancer Ther 2009 Nov; 8: 3036-3045

View manuscript (web link)

Daenen LG, et al. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther 2009 Oct; 8: 2872-2881

View manuscript (web link)

Burns CJ, et al. Discovery of CYT997: a structurally novel orally active microtubule targeting agent. Bioorg Med Chem Lett 2009 Aug 15; 19(16): 4639-4642

Posters and Abstracts

View abstract (PDF)

Powell AK, et al. Vascular targeting and anti-tumour efficacy of orally administered CYT997 in combination with cisplatin in a DLD-1 human colon adenocarcinoma xenograft model. 2010 Lorne Cancer Conference, Abstract

View abstract (web link)

Powell AK, et al. Antitumour activity of CYT997: A Phase II vascular disrupting agent administered orally in combination with cisplatin in a colon adenocarcinoma xenograft model. 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, Abstract A16

View abstract (web link)

Francesconi A. Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer. 2009 ASCO Annual Meeting, J Clin Oncol 27(15s), Abstract 3568

View abstract (web link)

Lickliter J, et al. Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancer. 2008 ASCO Annual Meeting, J Clin Oncol 26(May 20 suppl), Abstract 3504

View abstract (web link)

Malcontenti-Wilson C, et al. Selective targeting of tumor vasculature by the novel synthetic molecule CYT997 and its efficacy in preclinical cancer models. 2005 AACR Annual Meeting, Abstract 3429

link to PDF file

link to external website